

Immunohistochemistry (IHC) Market by Product (Antibodies (Type, Clonality), Reagents, Equipment, Kits, Software), Application (Diagnostics (Cancer, Infectious, Autoimmune, Neurological), Research (Drug Development), Forensic) - Global Forecast to 2029

Market Report | 2024-08-27 | 490 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global immunohistochemistry market is projected to reach USD 5.2 billion by 2029 from USD 3.7 billion in 2024, at a CAGR of 7.2% during the forecast period of 2024 to 2029. Factors propelling the growth of the market are the increased prevalence of cancer cases among the growing geriatric population and the rising application of IHC tests for the diagnosis and management of cancer. Moreover, the development of companion diagnostics (CDx) and its integration with IHC technology for the development of personalized medicine further support the expansion of the market. Application of IHC in supporting drug development and disease management to improve patient outcomes, along with ongoing research collaboration between pharmaceutical companies and academic institutes provide growth opportunities for players in the Immunohistochemistry Market.

"Histological Stain is expected to account for the largest share of by reagents segment."

In 2023, the histological stains market accounted for the largest share of the reagent subsegment within the product segment. In immunohistochemistry, histological stains are used to visualize and differentiate specific cellular components and structures within tissue samples. Histological stains are also used in multiplex staining also known as multiple staining. In this technique, more than one stains are used to detect multiple targets within a single tissue section. Apart from multiplex staining, histological stains are also used for cancer diagnosis by distinguishing normal and abnormal tissue morphology. These applications are major factors that drive the market for histological stains

"Research applications segment accounted for the second-largest share of the application segment."

In 2023, research applications accounted for the second-largest share of the application segment of the IHC market. In research, IHC technology is used for anti-tumor drug development and biomarker discovery. It helps researchers to identify the expression

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

of specific proteins and their locations within cells, aiding in the study of cancer and other diseases. For example, IHC is widely used to study the cancer proteome, which helps in finding new drug targets. Automated IHC platforms used in research offer consistent staining across slides, which is essential for reliable results. IHC techniques are also important in developmental studies, like embryological research, where they help visualize key proteins during the embryonic development phase. In stem cell research, IHC is used to monitor differentiation and proliferation markers, providing insights into stem cell behavior. Additionally, in drug testing, IHC helps evaluate the effects of new drugs on specific protein expressions within tissues. These applications highlight the important role of IHC in advancing scientific research and improving the understanding and treatment of various diseases.

"Asia Pacific is the fastest-growing region in the immunohistochemistry market."

The immunohistochemistry market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM), the Middle East, and Africa. Asia Pacific is the fastest-growing region in terms of CARG during the forecast period. The high growth rate of the region can be attributed to the fast adoption of the latest technologies such as advanced IHC products (like assays and diagnostic kits) in research and clinical applications. This factor, coupled with the increasing geriatric population, rising investments and funding for research activities, increasing disposable income, and developing academic and healthcare infrastructures in the region are key drivers for the high growth rate of the region.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 70% and Demand Side 30%

-□By Designation: Managers - 55%, CXOs - 20%, and Executives - 25%

-□By Region: North America -50%, Europe -20%, Asia-Pacific -20%, Latin America- 7%, Middle East and Africa-3%

Prominent Players in the Immunohistochemistry market are F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US).

Research Coverage:

This report provides a detailed picture of the immunohistochemistry market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immunohistochemistry market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, challenges, and opportunities.

The report provides insights on the following pointers:

-□Analysis of key drivers (Rising Geriatric Population and Increasing Cancer Prevalence, Innovations and advancements in Immunohistochemistry (IHC) Technology, Reimbursement Coverage for Immunohistochemistry (IHC) Tests, Rising Adoption of Digital Pathology), restraint (Adoption of alternative technologies and a high degree of consolidation), opportunities (Rising demand for personalized medicine, Growing adoption of companion diagnostics, Growth opportunities in emerging countries, Integration of artificial intelligence in IHC), Challenges (Stringent regulatory requirements, Lack of Standardization)

-□Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the Immunohistochemistry market.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the Immunohistochemistry market across varied regions.

-□Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Immunohistochemistry market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffman-La Roche Ltd (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US) among others in the Immunohistochemistry market. The report also helps stakeholders understand the pulse of the IHC market and provides them with information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.

Table of Contents:

1 INTRODUCTION 45

1.1 STUDY OBJECTIVES 45

1.2 MARKET DEFINITION 45

1.3 INCLUSIONS AND EXCLUSIONS 46

1.4 STUDY SCOPE 47

1.4.1 SEGMENTS COVERED 47

1.4.2 YEARS CONSIDERED 48

1.4.3 CURRENCY CONSIDERED 48

1.5 STAKEHOLDERS 48

1.6 SUMMARY OF CHANGES 49

2 RESEARCH METHODOLOGY 50

2.1 RESEARCH DATA 50

2.1.1 RESEARCH DESIGN 50

2.1.2 SECONDARY DATA 51

2.1.2.1 Secondary data sources 51

2.1.2.2 Objectives of secondary research 51

2.1.3 PRIMARY DATA 52

2.1.3.1 Objectives of primary research 52

2.2 MARKET SIZE ESTIMATION 53

2.2.1 REVENUE SHARE ANALYSIS (TOP-DOWN APPROACH) 54

2.2.2 INSIGHTS FROM PRIMARIES 55

2.3 MARKET GROWTH FORECAST 56

2.4 DATA TRIANGULATION 58

2.5 STUDY ASSUMPTIONS 58

2.6 RESEARCH LIMITATIONS 59

2.7 RISK ANALYSIS 59

3 EXECUTIVE SUMMARY 60

4 PREMIUM INSIGHTS 63

4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW 63

4.2 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION AND COUNTRY (2023) 64

4.3 IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 64

4.4 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2023 65

4.5 IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 65

?

5 MARKET OVERVIEW 66

5.1 INTRODUCTION 66

5.2 MARKET DYNAMICS 66

5.2.1	DRIVERS	67
5.2.1.1	Increasing prevalence of cancer and rising geriatric population	67
5.2.1.2	Technological innovations and advancements in immunohistochemistry diagnostics	70
5.2.1.3	Favorable reimbursement coverage for immunohistochemistry tests	71
5.2.1.4	Growing focus on digital pathology	72
5.2.2	RESTRAINTS	73
5.2.2.1	Adoption of alternative technologies in molecular diagnostics and research	73
5.2.2.2	Highly consolidated market	74
5.2.3	OPPORTUNITIES	75
5.2.3.1	Growing demand for precision/personalized medicines	75
5.2.3.2	Increasing adoption of companion diagnostics	76
5.2.3.3	Growth opportunities in emerging economies	76
5.2.3.4	Integration of AI in immunohistochemistry	77
5.2.4	CHALLENGES	77
5.2.4.1	Stringent regulatory requirements for tissue diagnostic instruments and consumables	77
5.2.4.2	Lack of standardization	77
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS	78
5.4	PRICING ANALYSIS	78
5.4.1	AVERAGE SELLING PRICE OF IMMUNOHISTOCHEMISTRY PRODUCTS, 2023	79
5.4.2	INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, 2021-2023	80
5.4.3	INDICATIVE SELLING PRICE TREND FOR IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2021-2023	80
5.5	TECHNOLOGY ANALYSIS	82
5.5.1	KEY TECHNOLOGIES	83
5.5.1.1	Automated immunohistochemistry systems	83
5.5.1.2	Multiplex immunohistochemistry	83
5.5.2	COMPLEMENTARY TECHNOLOGIES	83
5.5.2.1	Chromogenic detection	83
5.5.2.2	Fluorescent detection	84
5.5.3	ADJACENT TECHNOLOGIES	84
5.5.3.1	In situ hybridization	84
5.6	PATENT ANALYSIS	85
5.6.1	METHODOLOGY	85
5.6.2	INNOVATION AND PATENT APPLICATIONS	85
5.6.3	TOP PATENT APPLICANTS	85
?		
5.7	VALUE CHAIN ANALYSIS	88
5.7.1	RESEARCH & DEVELOPMENT	89
5.7.2	MANUFACTURING	89
5.7.3	LOGISTICS AND POST-SALES	89
5.8	SUPPLY CHAIN ANALYSIS	89
5.9	ECOSYSTEM ANALYSIS	90
5.9.1	ROLE OF RAW MATERIAL SUPPLIERS	91
5.9.2	ROLE OF PRODUCT PROVIDERS	92
5.9.3	ROLE OF END USERS	92
5.9.4	ROLE OF REGULATORY AUTHORITIES	93
5.10	PORTER'S FIVE FORCES ANALYSIS	93
5.10.1	INTENSITY OF COMPETITIVE RIVALRY	94

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.10.2	BARGAINING POWER OF SUPPLIERS	95
5.10.3	BARGAINING POWER OF BUYERS	95
5.10.4	THREAT OF SUBSTITUTES	95
5.10.5	THREAT OF NEW ENTRANTS	96
5.11	KEY STAKEHOLDERS AND BUYING CRITERIA	96
5.11.1	KEY STAKEHOLDERS IN BUYING PROCESS	96
5.11.2	KEY BUYING CRITERIA	97
5.12	REGULATORY LANDSCAPE	98
5.12.1	REGULATORY ANALYSIS	98
5.12.1.1	North America	98
5.12.1.1.1	US	98
5.12.1.1.2	Canada	100
5.12.1.2	Europe	100
5.12.1.3	Asia Pacific	102
5.12.1.3.1	Japan	102
5.12.1.3.2	China	103
5.12.1.3.3	India	103
5.12.1.4	Latin America	104
5.12.1.4.1	Brazil	104
5.13	KEY CONFERENCES AND EVENTS, 2024-2025	105
5.14	INVESTMENT AND FUNDING SCENARIO	107
5.15	IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET	107
6	IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING	110
6.1	INTRODUCTION	111
6.2	ANTIBODIES	111
6.2.1	IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE	114
6.2.2	PRIMARY ANTIBODIES	114
6.2.2.1	Increasing adoption of targeted immunotherapy to drive segment	114
6.2.3	SECONDARY ANTIBODIES	117
6.2.3.1	Better signal amplification and easier manufacturing process to fuel segment growth	117
6.2.4	IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY	120
6.2.5	MONOCLONAL ANTIBODIES	121
6.2.5.1	Increased applications in cancer diagnostics to support market growth	121
6.2.6	POLYCLONAL ANTIBODIES	124
6.2.6.1	Better sensitivity and higher resistant to changes in antigen conformation to augment segment growth	124
6.3	REAGENTS	126
6.3.1	HISTOLOGICAL STAINS	129
6.3.1.1	Growing focus on cancer diagnostics and developmental research to drive segment	129
6.3.2	BLOCKING SERA AND REAGENTS	132
6.3.2.1	Need to prevent non-specific binding and provide accurate outcomes to drive adoption	132
6.3.3	CHROMOGENIC SUBSTRATES	135
6.3.3.1	Rapid detection and faster diagnosis to propel segment growth	135
6.3.4	FIXATION REAGENTS	138
6.3.4.1	Increased focus on retaining tissue morphology and antigenicity of target molecules to support adoption	138
6.3.5	DILUENTS	141
6.3.5.1	Focus on reducing non-specific background staining during immunostaining to aid segment growth	141

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.3.6	ORGANIC SOLVENTS	144
6.3.6.1	Need to prevent physical damage in specimens and improve clarity in tissue sample visualization to drive market	144
6.3.7	PROTEOLYTIC ENZYMES	146
6.3.7.1	Proteolytic enzymes to improve accessibility of target antibodies	146
6.3.8	OTHER REAGENTS	149
6.4	EQUIPMENT	152
6.4.1	SLIDE-STAINING SYSTEMS	155
6.4.1.1	Availability of technologically advanced slide-staining systems to fuel segment growth	155
6.4.2	TISSUE PROCESSING SYSTEMS	158
6.4.2.1	High equipment cost and need for extensive regulatory compliance to limit market	158
6.4.3	SLIDE SCANNERS	161
6.4.3.1	Accurate insights into complexity of tissue interactions and multi-parameter cellular expressions to aid adoption	161
6.4.4	OTHER EQUIPMENT	164
6.5	KITS	166
6.5.1	HUMAN IMMUNOHISTOCHEMISTRY KITS	170
6.5.1.1	Increasing focus on cancer research to fuel segment growth	170
6.5.2	ANIMAL IMMUNOHISTOCHEMISTRY KITS	173
6.5.2.1	Rising focus on drug safety and efficacy in preclinical drug testing to boost segment growth	173
6.6	SOFTWARE	175
6.6.1	GROWING FOCUS ON DIGITAL PATHOLOGY FOR MORE ACCURATE DIAGNOSIS TO DRIVE MARKET	175
7	IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION	179
7.1	INTRODUCTION	180
7.2	DIAGNOSTIC APPLICATIONS	180
7.2.1	CANCER	184
7.2.1.1	Increasing target population and rising adoption of targeted therapies to propel market growth	184
7.2.2	INFECTIOUS DISEASES	188
7.2.2.1	High prevalence of infectious diseases and need for early diagnosis to aid market growth	188
7.2.3	NEPHROLOGICAL DISEASES	192
7.2.3.1	Rising prevalence of renal transplant-associated conditions to drive market	192
7.2.4	AUTOIMMUNE DISEASES	195
7.2.4.1	Focus on differentiating autoimmune diseases from similar clinical presentations to augment market growth	195
7.2.5	NEUROLOGICAL DISEASES	198
7.2.5.1	Increasing global burden of neurological disorders to spur market growth	198
7.2.6	OTHER DISEASES	201
7.3	RESEARCH APPLICATIONS	204
7.3.1	DRUG DEVELOPMENT AND TESTING	207
7.3.1.1	Need for accurate and objective outcomes in drug testing to augment segment growth	207
7.3.2	OTHER RESEARCH APPLICATIONS	210
7.4	FORENSIC APPLICATIONS	213
7.4.1	INCREASED DEMAND FOR EFFECTIVE DETERMINATION OF PATHOLOGICAL CHANGES TO SUPPORT MARKET GROWTH	213
8	IMMUNOHISTOCHEMISTRY MARKET, BY END USER	216
8.1	INTRODUCTION	217
8.2	HOSPITALS AND DIAGNOSTIC LABORATORIES	217
8.2.1	LOW COST OF SPECIALTY DIAGNOSTIC TESTS AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH	217
8.3	ACADEMIC & RESEARCH INSTITUTES AND CONTRACT RESEARCH ORGANIZATIONS	221
8.3.1	GROWING APPLICATION OF IMMUNOHISTOCHEMISTRY TESTS FOR DRUG DEVELOPMENT TO POSITIVELY IMPACT MARKET	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

GROWTH 221

8.4 OTHER END USERS 224

?

9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION 228

9.1 INTRODUCTION 229

9.2 NORTH AMERICA 229

9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 235

9.2.2 US 236

9.2.2.1 US to dominate North American immunohistochemistry market during forecast period 236

9.2.3 CANADA 240

9.2.3.1 High incidence of cancer and increased demand for advanced diagnostics to propel market growth 240

9.3 EUROPE 244

9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 249

9.3.2 GERMANY 250

9.3.2.1 High investments in life science R&D and favorable reimbursement policies to drive market 250

9.3.3 UK 254

9.3.3.1 Rising prevalence of cancer and increasing government funding in health research to augment market growth 254

9.3.4 FRANCE 258

9.3.4.1 Increased research in cancer diagnosis and treatment to support market growth 258

9.3.5 ITALY 263

9.3.5.1 Advanced health infrastructure and high geriatric population to fuel market growth 263

9.3.6 SPAIN 267

9.3.6.1 Increased demand for personalized medicines to boost adoption of immunohistochemistry products 267

9.3.7 REST OF EUROPE 270

9.4 ASIA PACIFIC 274

9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 280

9.4.2 CHINA 281

9.4.2.1 Increasing focus on advanced cancer diagnostics to spur market growth 281

9.4.3 JAPAN 285

9.4.3.1 High geriatric population and increased government healthcare expenditure to support market growth 285

9.4.4 INDIA 289

9.4.4.1 Need for high-end pathology and diagnostic services to propel market growth 289

9.4.5 AUSTRALIA 293

9.4.5.1 Increased patient population and high demand for quality healthcare to aid market growth 293

9.4.6 SOUTH KOREA 297

9.4.6.1 Focus on precision healthcare and personalized medicines to drive market 297

9.4.7 REST OF ASIA PACIFIC 301

9.5 LATIN AMERICA 305

9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 309

9.5.2 BRAZIL 310

9.5.2.1 Increasing incidence of chronic lifestyle diseases and rising investments by private companies to fuel market growth 310

9.5.3 MEXICO 314

9.5.3.1 Increasing research initiatives and rising cancer cases to drive market 314

9.5.4 REST OF LATIN AMERICA 318

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.6	MIDDLE EAST	322
9.6.1	MACROECONOMIC OUTLOOK FOR MIDDLE EAST	326
9.6.2	GCC COUNTRIES	327
9.6.2.1	Saudi Arabia	331
9.6.2.1.1	Growing cancer burden and increasing focus on research to augment market growth	331
9.6.2.2	UAE	334
9.6.2.2.1	Favorable government initiatives and high investments in healthcare infrastructure to fuel market growth	334
9.6.2.3	Rest of GCC Countries	338
9.6.3	REST OF MIDDLE EAST	342
9.7	AFRICA	345
9.7.1	RAPID RISE IN CANCER CASES AND HIGH HEALTHCARE INVESTMENTS TO DRIVE MARKET	345
9.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	349
10	COMPETITIVE LANDSCAPE	351
10.1	INTRODUCTION	351
10.2	KEY PLAYER STRATEGY/RIGHT TO WIN	351
10.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET	351
10.3	REVENUE ANALYSIS, 2021-2023	353
10.4	MARKET SHARE ANALYSIS, 2023	354
10.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	356
10.5.1	STARS	356
10.5.2	EMERGING LEADERS	356
10.5.3	PERVASIVE PLAYERS	356
10.5.4	PARTICIPANTS	356
10.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	358
10.5.5.1	Company footprint	358
10.5.5.2	Offering footprint	359
10.5.5.3	Application footprint	360
10.5.5.4	Region footprint	361
?		
10.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	362
10.6.1	PROGRESSIVE COMPANIES	362
10.6.2	RESPONSIVE COMPANIES	362
10.6.3	DYNAMIC COMPANIES	362
10.6.4	STARTING BLOCKS	362
10.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	364
10.7	COMPANY VALUATION AND FINANCIAL METRICS	366
10.7.1	FINANCIAL METRICS	366
10.7.2	COMPANY VALUATION	366
10.8	BRAND/PRODUCT COMPARISON	367
10.9	COMPETITIVE SCENARIO	368
10.9.1	PRODUCT LAUNCHES AND APPROVALS	368
10.9.2	DEALS	369
10.9.3	EXPANSIONS	370
10.9.4	OTHER DEVELOPMENTS	371
11	COMPANY PROFILES	372
11.1	KEY PLAYERS	372
11.1.1	F. HOFFMANN-LA ROCHE LTD.	372

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.1.1.1 Business overview 372
- 11.1.1.2 Products/Solutions offered 373
- 11.1.1.3 Recent developments 377
 - 11.1.1.3.1 Product launches and approvals 377
 - 11.1.1.3.2 Deals 379
- 11.1.1.4 MnM view 380
 - 11.1.1.4.1 Key strengths 380
 - 11.1.1.4.2 Strategic choices 380
 - 11.1.1.4.3 Weaknesses and competitive threats 380
- 11.1.2 DANAHER CORPORATION 381
 - 11.1.2.1 Business overview 381
 - 11.1.2.2 Products/Solutions offered 382
 - 11.1.2.3 Recent developments 386
 - 11.1.2.3.1 Product launches and approvals 386
 - 11.1.2.3.2 Deals 386
 - 11.1.2.4 MnM view 387
 - 11.1.2.4.1 Key strengths 387
 - 11.1.2.4.2 Strategic choices 387
 - 11.1.2.4.3 Weaknesses and competitive threats 387
- 11.1.3 AGILENT TECHNOLOGIES, INC. 388
 - 11.1.3.1 Business overview 388
 - 11.1.3.2 Products/Solutions offered 389
 - 11.1.3.3 Recent developments 393
 - 11.1.3.3.1 Product launches and approvals 393
 - 11.1.3.3.2 Deals 394
 - 11.1.3.3.3 Expansions 394
 - 11.1.3.4 MnM view 395
 - 11.1.3.4.1 Key strengths 395
 - 11.1.3.4.2 Strategic choices 395
 - 11.1.3.4.3 Weaknesses and competitive threats 395
- 11.1.4 PHC HOLDINGS CORPORATION 396
 - 11.1.4.1 Business overview 396
 - 11.1.4.2 Products/Solutions offered 397
 - 11.1.4.3 Recent developments 402
 - 11.1.4.3.1 Deals 402
 - 11.1.4.3.2 Other developments 403
 - 11.1.4.4 MnM view 403
 - 11.1.4.4.1 Key strengths 403
 - 11.1.4.4.2 Strategic choices 403
 - 11.1.4.4.3 Weaknesses and competitive threats 403
- 11.1.5 THERMO FISHER SCIENTIFIC INC. 404
 - 11.1.5.1 Business overview 404
 - 11.1.5.2 Products/Solutions offered 405
- 11.1.6 MERCK KGAA 409
 - 11.1.6.1 Business overview 409
 - 11.1.6.2 Products/Solutions offered 410

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.1.7	BIO-RAD LABORATORIES, INC.	417
11.1.7.1	Business overview	417
11.1.7.2	Products/Solutions offered	418
11.1.8	BIO-TECHNE	422
11.1.8.1	Business overview	422
11.1.8.2	Products/Solutions offered	423
11.1.8.3	Recent developments	426
11.1.8.3.1	Deals	426
11.1.8.3.2	Expansions	426
11.1.8.3.3	Other developments	426
11.1.9	BECTON, DICKINSON AND COMPANY	427
11.1.9.1	Business overview	427
11.1.9.2	Products/Solutions offered	428
11.1.9.3	Recent developments	432
11.1.9.3.1	Expansions	432
11.1.10	TAKARA BIO INC.	433
11.1.10.1	Business overview	433
11.1.10.2	Products/Solutions offered	434
11.1.11	ENZO BIOCHEM INC.	438
11.1.11.1	Business overview	438
11.1.11.2	Products/Solutions offered	439
11.1.11.3	Recent developments	441
11.1.11.3.1	Expansions	441
11.1.12	SINO BIOLOGICAL, INC.	442
11.1.12.1	Business overview	442
11.1.12.2	Products/Solutions offered	442
11.1.12.3	Recent developments	443
11.1.12.3.1	Expansions	443
11.1.13	SAKURA FINETEK JAPAN CO., LTD.	444
11.1.13.1	Business overview	444
11.1.13.2	Products/Solutions offered	444
11.1.13.3	Recent developments	447
11.1.13.3.1	Product launches	447
11.1.13.3.2	Deals	449
11.1.14	CELL SIGNALING TECHNOLOGY, INC.	450
11.1.14.1	Business overview	450
11.1.14.2	Products/Solutions offered	450
11.1.14.3	Recent developments	453
11.1.14.3.1	Deals	453
11.1.15	BIO SB	454
11.1.15.1	Business overview	454
11.1.15.2	Products/Solutions offered	454
11.1.15.3	Recent developments	459
11.1.15.3.1	Product launches	459
11.1.16	MILTENYI BIOTEC	460
11.1.16.1	Business overview	460
11.1.16.2	Products/Solutions offered	460

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.1.17	ORIGENE TECHNOLOGIES, INC.	463
11.1.17.1	Business overview	463
11.1.17.2	Products/Solutions offered	463
11.2	OTHER PLAYERS	468
11.2.1	EAGLEBIO	468
11.2.2	BIOCARE MEDICAL, LLC	469
11.2.3	ELABSCIENCE BIONOVATION INC.	471
11.2.4	BIOGENEX	473
11.2.5	DIAGNOSTIC BIOSYSTEMS INC.	475
11.2.6	HISTO-LINE LABORATORIES	477
11.2.7	ROCKLAND IMMUNOCHEMICALS, INC.	479
11.2.8	CANDOR BIOSCIENCE GMBH	480
11.2.9	GENEMED BIOTECHNOLOGIES, INC.	481
12	APPENDIX	482
12.1	DISCUSSION GUIDE	482
12.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	486
12.3	CUSTOMIZATION OPTIONS	488
12.4	RELATED REPORTS	488
12.5	AUTHOR DETAILS	489

**Immunohistochemistry (IHC) Market by Product (Antibodies (Type, Clonality),
Reagents, Equipment, Kits, Software), Application (Diagnostics (Cancer, Infectious,
Autoimmune, Neurological), Research (Drug Development), Forensic) - Global
Forecast to 2029**

Market Report | 2024-08-27 | 490 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

Signature